Home › Funds › GKV Capital Management Co., Inc. › AZN
GKV Capital Management Co., Inc. position in AZN
Astrazeneca PLC · Health Care
GKV Capital Management Co., Inc. reported holding 12,905 shares of AZN (Astrazeneca PLC) in its Q3 2026 13F filing — a position valued at US$2.1M, representing 0.68% of its reported portfolio and ranking #45 among its reported holdings. GKV Capital Management Co., Inc. has disclosed AZN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR
How GKV Capital Management Co., Inc.'s AZN position evolved
GKV Capital Management Co., Inc. first disclosed a stake in AZN in Q4 2025 at 9,000 shares (US$827K). The position peaked in Q2 2026 at 11,245 shares, worth US$2.1M. Across 4 filings, GKV Capital Management Co., Inc. increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 12,905 shares valued at US$2.1M — an increase of 1,660 shares quarter over quarter.. Notable position changes include a 53% increase in Q2 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 9.00K | $827.37K | New |
| Q1 2026 | 7.34K | $1.43M | Reduce |
| Q2 2026 | 11.24K | $2.11M | Add |
| Q3 2026 | 12.90K | $2.10M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AZN and 13F data
AZN (Astrazeneca PLC) is a Health Care company. 70 other funds we track also report a position in AZN — the largest reported positions include Evelyn Partners Group Ltd (US$41.52B), Banque Cantonale Vaudoise (US$11.31B), INVESTOR AB (US$9.78B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AZN
- Evelyn Partners Group Ltd 2.24M sh · $41.52B · Q2 2026
- Banque Cantonale Vaudoise 60.46K sh · $11.31B · Q2 2026
- INVESTOR AB 51.59M sh · $9.78B · Q2 2026
- Capital International Investors 34.58M sh · $6.49B · Q2 2026
- Norges Bank Investment Management 33.86M sh · $6.33B · Q2 2026
- Capital World Investors 30.08M sh · $5.63B · Q2 2026
- Capital World Investors 30.08M sh · $5.63B · Q2 2026
- Wellington Management Group 28.54M sh · $5.36B · Q2 2026
- WELLINGTON MANAGEMENT GROUP LLP 28.54M sh · $5.36B · Q2 2026
- Legal & General Investment Management America 25.75M sh · $4.82B · Q2 2026
- VANGUARD ASSET MANAGEMENT, Ltd 18.71M sh · $3.49B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 18.10M sh · $3.43B · Q2 2026
More on GKV Capital Management Co., Inc.
FAQ
How long has GKV Capital Management Co., Inc. held AZN?
GKV Capital Management Co., Inc. has disclosed AZN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is GKV Capital Management Co., Inc.'s current position in AZN?
As of Q3 2026, GKV Capital Management Co., Inc. holds 12.90K shares of AZN (Astrazeneca PLC), valued at $2.10M, representing 0.68% of its reported portfolio and ranking #45.
Has GKV Capital Management Co., Inc. been buying or selling AZN?
In the latest 13F filing (Q3 2026), GKV Capital Management Co., Inc. increased its position in AZN. The position peaked in Q2 2026 at 11.24K shares.
Which other funds hold AZN?
Other major institutional holders of AZN include Evelyn Partners Group Ltd, Banque Cantonale Vaudoise, INVESTOR AB, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.